Holocene Advisors’s Medifast MED Stock Holding History

Holocene Advisors’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-5,626	Closed	-$583K	–	804
2023 Q1	$583K	Sell	5,626 -7,602	-57%	-$842K	﹤0.01%	637
2022 Q4	$1.53M	Buy	13,228 +455	+4%	+$53K	0.01%	487
2022 Q3	$1.38M	Sell	12,773 -462	-3%	-$66.2K	0.01%	538
2022 Q2	$2.39M	Buy	13,235 +4,727	+56%	+$846K	0.01%	491
2022 Q1	$1.45M	Buy	8,508 +3,359	+65%	+$633K	0.01%	608
2021 Q4	$1.08M	Buy	+5,149	New	+$1.06M	0.01%	667
2020 Q3	–	Sell	-4,543	Closed	-$630K	–	736
2020 Q2	$630K	Buy	+4,543	New	+$417K	0.01%	492
2019 Q1	–	Sell	-1,923	Closed	-$240K	–	737
2018 Q4	$240K	Buy	+1,923	New	+$329K	﹤0.01%	597

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Holocene Advisors's MED Position: Q2 2023 in Review

Holocene Advisors sold out of Medifast (MED) in Q2 2023, closing a stake of 5,626 shares — an estimated $583K sold.

Holocene Advisors first reported a position in MED in Q4 2018 and held it in 8 quarters. The position peaked at $2.39M in Q2 2022. 236 funds tracked by Wall St. Rank hold MED as of Q2 2023.

Holocene Advisors reported no remaining Medifast position as of Q2 2023 after selling out during the quarter.
Holocene Advisors sold 5,626 Medifast shares in Q2 2023, an estimated $583K.
Holocene Advisors first reported a position in Medifast in Q4 2018 and held it in 8 quarters.
Holocene Advisors's Medifast position peaked at $2.39M in Q2 2022.
236 funds tracked by Wall St. Rank held Medifast as of Q2 2023.

Based on Holocene Advisors's 13F filing for Q2 2023, filed 14 Aug 2023.